Cargando…

A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab

Nivolumab, an immune checkpoint inhibitor is the first-line therapy for platinum-resistant recurrent/metastatic head and neck cancer, and highly effective for some patients. However, no factors have been identified that could predict response or prognosis after nivolumab administration. We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuba, Kiyomi, Inoue, Hitoshi, Matsumura, Satoko, Enoki, Yuichiro, Kogashiwa, Yasunao, Ebihara, Yasuhiro, Nakahira, Mitsuhiko, Yamazaki, Tomoko, Yasuda, Masanari, Kaira, Kyoichi, Kagamu, Hiroshi, Sugasawa, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800384/ https://www.ncbi.nlm.nih.gov/pubmed/36581686 http://dx.doi.org/10.1038/s41598-022-27237-0

Ejemplares similares

Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2023)

Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2023)

Identification of novel oncogenes in oral cancer among elderly nonsmokers
por: Inoue, Hitoshi, et al.
Publicado: (2023)

Acquired Hemophilia A Presenting as Massive Postoperative Bleeding in a Patient with Oral Squamous Cell Carcinoma
por: Oba, Susumu, et al.
Publicado: (2020)

Primary Small Cell Carcinoma of the Hypopharynx: A Report of Two Cases and Review of Nine Additional Cases
por: Nakahira, Mitsuhiko, et al.
Publicado: (2017)

Podoplanin is an efficient predictor of neck lymph node metastasis in tongue squamous cell carcinoma with low tumor budding grade
por: Hamada, Mei, et al.
Publicado: (2020)

Prediction Formula for Pathological Depth of Invasion From Clinical Depth of Invasion in Tongue Squamous Cell Carcinoma (SCC) Stage I/II Cases
por: Hamada, Mei, et al.
Publicado: (2023)

Significance of PD-L1 Expression in Tongue Cancer Development
por: Yoshida, Saori, et al.
Publicado: (2018)

Extratemporal Malignant Nerve Sheath Tumor of Facial Nerve with Coexistent Intratemporal Neurofibroma Mimicking Malignant Intratemporal Extension
por: Nakahira, Mitsuhiko, et al.
Publicado: (2015)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features
por: Shiono, Ayako, et al.
Publicado: (2020)

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019)

Immunohistochemical Analysis of Oral Dysplasia: Diagnostic Assessment by Fascin and Podoplanin Expression
por: Shimamura, Yumiko, et al.
Publicado: (2011)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Spontaneous aspiration of a long tree twig as foreign body
por: Hashimoto, Kosuke, et al.
Publicado: (2019)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Head and Neck Cancer with Dermatomyositis: A Report of Two Clinical Cases
por: Yamauchi, Kohichi, et al.
Publicado: (2010)

The Effect of Topical Application of Royal Jelly on Chemoradiotherapy-Induced Mucositis in Head and Neck Cancer: A Preliminary Study
por: Yamauchi, Kohichi, et al.
Publicado: (2014)

Sentinel Node Biopsy for the Head and Neck Using Contrast-Enhanced Ultrasonography Combined with Indocyanine Green Fluorescence in Animal Models: A Feasibility Study
por: Kogashiwa, Yasunao, et al.
Publicado: (2015)

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
por: Kaira, Kyoichi, et al.
Publicado: (2020)

Results of definitive radiotherapy with concurrent chemotherapy for maxillary sinus carcinomas with neck lymph node metastasis
por: Abe, Takanori, et al.
Publicado: (2020)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
por: Mouri, Atsuto, et al.
Publicado: (2019)

Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC
por: Kaira, Kyoichi, et al.
Publicado: (2022)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
por: Tsukagoshi, Mariko, et al.
Publicado: (2020)

Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents
por: Kawata-Shimamura, Yumiko, et al.
Publicado: (2022)

An Endoscopic Endonasal Approach for Early-Stage Olfactory Neuroblastoma: An Evaluation of 2 Cases with Minireview of Literature
por: Yokoi, Hidenori, et al.
Publicado: (2015)

Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report
por: Kobayashi, Kunihiko, et al.
Publicado: (2021)

Establishing a whole blood CD4(+) T cell immunity measurement to predict response to anti-PD-1
por: Yamaguchi, Ou, et al.
Publicado: (2022)

Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer
por: Kaira, Kyoichi
Publicado: (2022)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
por: Hashimoto, Kosuke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d178s980bpf90hnnulm0vhmt3n